BC
ANAB icon

Broadfin Capital’s AnaptysBio ANAB Stock Holding History

Broadfin Capital’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$3.6M Buy
+221,600
New +$5.24M 0.48% 35
2018
Q2 		– Sell
-79,200
Closed -$8.24M – 47
2018
Q1 		$8.24M Buy
+79,200
New +$8.93M 1.28% 24

Other funds holding ANAB

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Broadfin Capital's ANAB Position: Q4 2019 in Review

Broadfin Capital opened a new position in AnaptysBio (ANAB) in Q4 2019: 221,600 shares worth $3.6M. The stake represents 0.48% of the portfolio and ranks #35 among its holdings. This is a return to the name: Broadfin Capital previously reported a position in ANAB as recently as Q1 2018.

Broadfin Capital first reported a position in ANAB in Q1 2018 and has held it in 2 quarters since. The position peaked at $8.24M in Q1 2018. 121 funds tracked by Wall St. Rank hold ANAB as of Q4 2019.

  • Broadfin Capital held 221,600 shares of AnaptysBio worth $3.6M as of Q4 2019.
  • AnaptysBio was a new Broadfin Capital position in Q4 2019.
  • AnaptysBio made up 0.48% of Broadfin Capital's portfolio in Q4 2019, its #35 holding.
  • Broadfin Capital first reported a position in AnaptysBio in Q1 2018 and has held it in 2 quarters since.
  • Broadfin Capital's AnaptysBio position peaked at $8.24M in Q1 2018.
  • 121 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.